Breast Cancer Therapies: An Overview of Emerging Treatment Approaches, Clinical Trials, and Comorbidity Management
Year: 2025
Type: article
Abstract: rate is disproportionately high in low-and middle-income countries, where survival outcomes are compromised by delayed diagnosis, limited access to effective treatments, and inadequate healthcare infrastructure.For instance, while high-income countries have seen a steady decline in mortality rates due to early detection and advanced therapies, survival rates are much lower in regions like South Asia and sub-Saharan Africa.Globally, the five-year relative survival rate for breast cancer ranges from over 90% in developed countries to less than 60% in some developing regions.Bridging this gap remains critical, requiring increased investment in early detection, equitable access to treatment, and public health awareness campaigns [1]. Current Treatment ApproachesBreast cancer treatment approaches are tailored based on the stage, type, and molecular characteristics of the tumor, as well as the overall health and preferences of the patient (Figure 2 and table 1) [2, 3].For early-stage breast cancer (Stages I and II), surgery is often the AbstractBreast cancer is one of the most common cancers worldwide, with a significant burden on public health, accounting for a substantial number of diagnoses and deaths each year.The disease's prevalence varies by geographical region, but it remains a leading cause of cancer-related mortality, especially in women.Current treatment approaches for breast cancer include surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapies, and immunotherapy.These therapies have led to improved survival rates for many patients, particularly those with hormone receptor-positive (HR+) tumors.However, challenges persist, particularly for aggressive subtypes such as triple-negative breast cancer (TNBC), which remain difficult to treat with conventional therapies.Clinical trials continue to explore novel agents and combination therapies to improve outcomes, with a focus on precision medicine and personalized treatment strategies that consider the tumor's molecular profile.Furthermore, comorbidities play a critical role in the management of breast cancer, as underlying health conditions can significantly impact treatment effectiveness and patient outcomes.Conditions such as diabetes, hypertension, cardiovascular disease, and obesity are common in breast cancer patients and can complicate treatment regimens, leading to adverse reactions or the need for adjustments in therapy.Diabetes can alter drug metabolism, reducing the effectiveness of chemotherapy and endocrine therapies.Cardiovascular conditions can limit the use of certain chemotherapies that have cardiotoxic side effects.The presence of autoimmune diseases or chronic pain can also affect treatment adherence and patient quality of life.Integrating care for comorbidities alongside cancer treatment is essential to ensure optimal outcomes, reduce treatment-related risks, and enhance the overall well-being of breast cancer patients.
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4410614573